These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38030508)

  • 1. [Can academic structures improve access to CAR-T cells?].
    Le Guen C; Grain A; Le Calvez B; Saiagh S; Vrignaud F; Eveillard M; Clémenceau B; Zahar MB
    Bull Cancer; 2024 Jan; 111(1):62-72. PubMed ID: 38030508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Requirements for academic production of CAR-T cells in accordance with Good Pharmaceutical Practice (GMP). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Deschamps M; Decot V; Giverne C; Pinturaud M; Vaissié A; Parquet N; Olivero S; Anne-Claire M; Bay JO; Yakoub-Agha I; Ferrand C
    Bull Cancer; 2020 Jan; 107(1S):S85-S93. PubMed ID: 31547937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GMP-Compliant Procedure for the Generation of Gene-Modified T cells.
    Savvopoulos N; Stampolitis K; Alexandropoulos G; Kefala D; Lysandrou M; Zacharioudaki V; Tsolakos N; Spyridonidis A
    J Vis Exp; 2023 Oct; (200):. PubMed ID: 37870303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
    Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
    Front Immunol; 2020; 11():482. PubMed ID: 32528460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors.
    Syed F; El Fakih R; Alahmari AD; Osman Ali AS; Aljurf M
    Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):137-152. PubMed ID: 36395497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CAR-T cells gene therapy medicines: Regulatory status and pharmaceutical circuits in Europe and France].
    de Jorna R; Madelaine I; Larghero J; Mebarki M
    Bull Cancer; 2021 Oct; 108(10S):S162-S167. PubMed ID: 34920799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects.
    Poorebrahim M; Sadeghi S; Fakhr E; Abazari MF; Poortahmasebi V; Kheirollahi A; Askari H; Rajabzadeh A; Rastegarpanah M; Linē A; Cid-Arregui A
    Crit Rev Clin Lab Sci; 2019 Sep; 56(6):393-419. PubMed ID: 31314617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CAR T cells as drugs for novel therapies (advanced therapy medicinal products)].
    Köhl U; Abken H
    Internist (Berl); 2021 Apr; 62(4):449-457. PubMed ID: 33590292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T-Cell Production Using Nonviral Approaches.
    Lukjanov V; Koutná I; Šimara P
    J Immunol Res; 2021; 2021():6644685. PubMed ID: 33855089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.
    Prommersberger S; Monjezi R; Shankar R; Schmeer M; Hudecek M; Ivics Z; Schleef M
    Methods Mol Biol; 2022; 2521():25-39. PubMed ID: 35732991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
    Schmidts A; Marsh LC; Srivastava AA; Bouffard AA; Boroughs AC; Scarfò I; Larson RC; Bedoya F; Choi BD; Frigault MJ; Bailey SR; Leick MB; Vatsa S; Kann MC; Prew MS; Kleinstiver BP; Joung JK; Maus MV
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.
    Nicod C; da Rocha MN; Warda W; Roussel X; Haderbache R; Seffar E; Trad R; Bouquet L; Goncalves M; Bosdure L; Laude MC; Guiot M; Ferrand C; Deschamps M
    Curr Res Transl Med; 2023; 71(2):103385. PubMed ID: 36773434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
    Yakoub-Agha I
    Curr Res Transl Med; 2018 May; 66(2):57-58. PubMed ID: 29685843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells.
    Holzinger A; Abken H
    Pharmacology; 2022; 107(9-10):446-463. PubMed ID: 35696994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The paths toward non-viral CAR-T cell manufacturing: A comprehensive review of state-of-the-art methods.
    Metanat Y; Viktor P; Amajd A; Kaur I; Hamed AM; Abed Al-Abadi NK; Alwan NH; Chaitanya MVNL; Lakshmaiya N; Ghildiyal P; Khalaf OM; Ciongradi CI; Sârbu I
    Life Sci; 2024 Jul; 348():122683. PubMed ID: 38702027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.
    Agarwalla P; Ogunnaike EA; Ahn S; Ligler FS; Dotti G; Brudno Y
    Adv Healthc Mater; 2020 Jul; 9(14):e2000275. PubMed ID: 32592454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of CAR-T cells using lentiviral vectors.
    Poorebrahim M; Quiros-Fernandez I; Fakhr E; Cid-Arregui A
    Methods Cell Biol; 2022; 167():39-69. PubMed ID: 35152998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.